In vitro diagnostics firm bioMérieux has announced the launch of SPINCHIP, an innovative point-of-care platform, featuring its first test for the measurement of high-sensitivity cardiac troponin I from a single drop of blood.
Presented for the first time at the European Society of Emergency Medicine (EUSEM) Congress in Paris, this rapid diagnostic solution will initially be available in Europe, bringing a critical test closer to the point of care and helping emergency teams quickly triage adult patients with suspected acute myocardial infarction.
SPINCHIP is a compact immunoassay platform for point-of-care testing outside traditional laboratories. Its first test, SPINCHIP hs-cTnI, enables high-sensitivity measurement of the cardiac marker troponin I to accelerate clinical decision-making, allowing for rapid and confident triage of adult patients with suspected acute myocardial infarction.
With a turnaround time of around 10 minutes, SPINCHIP speeds up patient triage, helping streamline care pathways, relieve pressure on emergency departments, and optimise the use of hospital resources. The technology is based on a test capable of providing a highly accurate result from a single drop of capillary blood - a major advantage for both patient comfort and ease of use.
The platform can be used by all emergency care professionals while offering analytical performance comparable to that of laboratory instruments. Its intuitive operation consists of three steps: collecting a drop of blood from the fingertip using a cartridge barely larger than a coin, inserting the cartridge into the device, and reading the result after 10 minutes. The SPINCHIP solution is designed to connect to hospital information systems to facilitate traceability and the integration of results into the patient’s care pathway, under the supervision of clinical laboratory scientists.
“With SPINCHIP, we’re bringing our long-standing expertise in immunoassays directly to emergency departments, closer to the patient. This innovation reflects our ongoing commitment to point-of-care testing: to help improve patient care while assisting healthcare systems in better organizing their resources,” said Pierre Boulud, CEO of bioMérieux.
One year after acquiring the Norwegian company SpinChip Diagnostics, bioMérieux is taking a new step forward in the development of its point-of-care testing portfolio. The SPINCHIP solution, which is part of the company’s GO•28 strategic plan, will contribute to bioMérieux’s long-term growth, well beyond 2028.
Officially CE-marked in accordance with the IVDR regulation, the SPINCHIP hs-cTnl test is initially being launched in Europe, before a gradual rollout outside the European Union.